fbpx
Tabelecleucel, tab-cel® - Atara Biotherapeutics pipeline - investigational Epstein-Barr virus associated post-transplant lymphoproliferative disease disorder EBV PTLD T-cell immunotherapy

Publications and Presentations

Publications and presentations may be available. Please contact us at MedInfo@atarabio.com (medical professionals and patients) or IR@atarabio.com (investors and media) for more information.

Abstract 4071: Presented December 9, 2019 at 61st American Society of Hematology (ASH) Annual Meeting

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program
Susan Prockop, Ran Reshef, Donald E. Tsai, Nancy Bunin, Rolla Abu-Arja, Kris Michael Mahadeo, Wen-Kai Weng, Koen Van Besien, David Loeb, Sunita Dwivedy Nasta, Eneida R. Nemecek, Minoti Hiremath, Susan Yue, Yan Sun, Willis H Navarro, Sarah Nikiforow

Abstract 65: Presented December 7, 2019 at 61st American Society of Hematology (ASH) Annual Meeting

Burden of Hospitalizations Due to Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+ PTLD) in Patients Who Failed First Line Rituximab or Rituximab Plus Chemotherapy Following Solid Organ Transplant (Post-SOT): A Retrospective Chart Review Study of German PTLD Registry
Heiner Zimmermann, Hairong Xu, Arie Barlev, Yang Zhang, Dhanalakshmi Thirumalai, Crystal Watson, Ralf Ulrich Trappe

Abstract 5826: Publication only in Blood Journal’s ASH 2019 annual meeting abstract supplement

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States; A Comprehensive Literature Review
Crystal Watson, Arie Barlev, Jodie Worrall, Steve Duff, Rachel Beckerman

Poster #PRO145: Presented November 6, 2019 at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2019

The Humanistic Burden of Short-term Adverse Events Associated With the CHOP Chemotherapy Regimen in Patients With Lymphoproliferative Disorders in European Countries: A Comprehensive Literature Review
Crystal Watson, Arie Barlev, Jodie Worrall, Steve Duff, Rachel Beckerman

Poster #PRO50: Presented November 6, 2019 at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2019

The Economic Burden of Short-term Adverse Events Associated With the CHOP Chemotherapy Regimen in Patients With Lymphoproliferative Disorders in European Countries: a Comprehensive Literature Review
Crystal Watson, Arie Barlev, Jodie Worrall, Steve Duff, Rachel Beckerman

Poster #PCN480: Presented November 4, 2019 at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2019

Relevance of Selected Patient-Reported Outcome (PRO) Measures in Epstein-Barr Virus Driven Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Patients
Watson C, Trivedi B, Barlev A, Cole J

Poster #1061: Presented October 21, 2019 at International Society for Quality of Life Research (ISOQOL) 26th Annual Conference

Impact of Disease on Patient Functioning in Epstein-Barr Virus Associated (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) Patients
B Trivedi, C Watson, A Barlev, J Cole

Abstract PF719: Presented June 14, 2019 at 24th Congress of European Hematology Association (EHA)

Clinical Outcomes of Solid Organ Transplant Patients with EBV+PTLD Who Fail First-Line Rituximab or Rituximab Plus Chemotherapy: An Analysis of German PTLD Registry.
Heiner Zimmermann , Hairong Xu , Arie Barlev , Amy Feng , Xiaoming Li , Willis Navarro , Ralf Ulrich Trappe

Poster Board #176, Abstract 2532: Presented June 1, 2019 at ASCO 2019 Annual Meeting

Correlation of circulating EBV-targeted cytotoxic T lymphocyte precursors (EBV-CTLp) and clinical response following tabelecleucel (tab-cel) infusion in patients with EBV-driven disease.
Blake T. Aftab, Daniel Munson, Kevin Rasor, Philippe Foubert, Donald Edward Tsai, Wen-Kai Weng, Armin Ghobadi, Koen Van Besien, Yan Sun, Minoti Hiremath, Willis H. Navarro, Susan Prockop

Poster Board #79b, Abstract TPS6092: Presented June 1, 2019 at ASCO 2019 Annual Meeting

Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV+NPC).
Lillian L. Siu, Joshua Bauml, Douglas Adkins, A. Dimitrios Colevas, Cesar Augusto Perez, Jennifer Hsing Choe, Yang Zhang, Wen Shi, Willis H. Navarro, Missak Haigentz, Guilherme Rabinowits, David G. Pfister

Presentation Number 34O: December 15, 2018 at ESMO Immuno-Oncology Congress 2018

Efficacy and safety of tabelecleucel in patients with Epstein Barr Virus-associated leiomyosarcomas (EBV+ LMS)
L.S. Kurlander, A. Srinivasan, A. Ghobadi, S. Suser, E. Doubrovina, F. Boulad, L. Mascarenhas, M. Laquaglia, A. Price, G. Behr, B. Shulkin, A. Sudhindra, Y. Wei, M. Hiremath, W. Navarro, R. O’Reilly, S. Prockop

Abstract 4590: Presented on December 3, 2018 at 60th American Society of Hematology (ASH) Annual Meeting

Adoptive Therapy with EBV-Specific T Cells for Treatment of CNS EBV Post-Transplant Lymphoproliferative Disease Arising after Hematopoietic Stem Cell Transplant or Solid Organ Transplant
Susan Prockop, Stephanie Suser, Ekaterina Doubrovina, Hugo R. Castro-Malaspina, Esperanza B. Papadopoulos, James W. Young, Victoria Szenes, Alison Slocum, Karim Baroudy, Richard J. O’Reilly

Abstract 4777: Presented on December 3, 2018 at 60th American Society of Hematology (ASH) Annual Meeting

Treatment Patterns for Patients with Post-Transplant Lymphoproliferative Disorder Who Fail Rituximab after Allogeneic Hematopoietic Stem Cell Transplantation: Findings from a Systematic Literature Review
Hairong Xu, Crystal Watson, Shan Ashton Garib, Anna Forsythe, Arie Barlev

Abstract 3556: Presented on December 2, 2018 at 60th American Society of Hematology (ASH) Annual Meeting

Estimating Long-Term Survival in a Cohort of Allogeneic Hematopoietic Stem Cell Transplant Patients
Stephen Palmer, Casey Quinn, Crystal Watson, Arie Barlev

Abstract 4596: Presented on December 3, 2018 at 60th American Society of Hematology (ASH) Annual Meeting

Dual-Sensitized T-Cells Responding to EBV Blcl and Either CMVpp65 or WT-1 Peptide Pools Have Distinct or Shared HLA Restrictions That May Depend on the Presenting HLA Alleles
Ekaterina Doubrovina, Aisha N. Hasan, Susan Prockop, Karim Baroudy, Richard O’Reilly

Abstract 5841: Publication only in Blood Journal’s ASH 2018 annual meeting abstract supplement

Younger Patients Are Impacted By Post-Transplant Lymphoproliferative Disorder: Findings from a Systematic Literature Review of Real-World Evidence
Crystal Watson, Hairong Xu, Anna Forsythe, Shan Ashton Garib, Arie Barlev

Abstract 5840: Publication only in Blood Journal’s ASH 2018 annual meeting abstract supplement

Risk of Patients Developing Post-Transplant Lymphoproliferative Disorder within the First Year after an Allogeneic Hemopoietic Stem Cell Transplant, 2011 to 2016: A US Claims Database Analysis
Arie Barlev, Hairong Xu, Nicole Fulcher, Crystal Watson, Ila Sruti, Akshay Sudhindra

Abstract 5839: Publication only in Blood Journal’s ASH 2018 annual meeting abstract supplement

A Systematic Literature Review of Real-World Evidence in Post-Transplant Lymphoproliferative Disorder
Hairong Xu, Anna Forsythe, Arie Barlev, Nazia Rashid, Crystal Watson

Abstract PF401. Presented on June 15, 2018 at 23rd Congress of the European Hematology Association (EHA)

Long Term Outcomes of Tabelecleucel (Allogeneic Third-Party EBV-Targeted Cytotoxic Tn Lymphocytes) for Rituximab-Refractory Post-Transplant EBV+ Lymphomas: A Single Center Experience
Susan Prockop, Ekaterina Doubrovina, Amy Feng, Guenther Koehne, Parastoo Dahi, Esperanza Papadopoulos, Craig Sauter, Stephanie Suser, Willis Navarro, Akshay Sudhindra, Richard O’Reilly

Abstract A219. Presented on March 19, 2018 at 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Lisbon, Portugal

Burden of Post-Transplant Lymphoproliferative Disorder-Mortality After Allogeneic Hematopoietic Cell Transplantation
Aaron Katz, Arie Barlev, AJ Joshi

Abstract 4520. Presented on December 11, 2017 at 59th American Society of Hematology Annual Meeting and Exposition (ASH), Atlanta, GA

Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder
Susan Prockop, Ai Li, Robert Baiocchi, Nancy Bunin, Kris Michael Mahadeo, Eneida R. Nemecek, Sarah Nikiforow, Ran Reshef, Donald Edward Tsai, Willis H. Navarro, Richard J. O’Reilly

Am J Transplant 2016;16 (suppl 3; abstr 575). Presented on June 13, 2016 at 2016 American Transplant Congress, Boston, MA..

Banked EBV-Specific T-Cells for Treatment of Rituximab Refractory EBV+ B-Cell Lymphoma in Solid Organ Transplantation Recipients
Prockop S, Doubrovina E, Sauter C, Suser S, O’Reilly R.

Abstract 3012. Presented on June 6, 2016 at 2016 American Society of Clinical Oncology Annual Meeting, Chicago, IL.

Treatment of EBV+ nasopharyngeal carcinoma with banked EBV-specific cytotoxic T cells
Susan Prockop, Ekatarina Doubrovina, Shrujal S. Baxi, Virginia Escobedo, Stephanie Suser, Victoria Szenes, David G. Pfister, Richard J. O’Reilly

J Clin Oncol 33, 2015 (suppl; abstr 10016). Presented on June 1st, 2015 at the 2015 American Society of Clinical Oncology Annual Meeting, Chicago, IL.

Banked EBV-specific T-cells from HLA-partially matched normal donors to induce durable remissions of rituximab refractory EBV+ B-cell lymphomas post hematopoietic and organ allografts.
Prockop, S. et al.

Abstract CT107. Presented on April 19th, 2015 at the American Association for Cancer Research Annual Meeting 2015, Philadelphia, PA.

Epstein-Barr virus-specific cytotoxic T lymphocytes for treatment of rituximab-refractory Epstein-Barr virus-associated lymphoproliferative disorder.
Prockop, S. et al.

Haematologica. 2014 Feb; 99(2): 346–352.doi: 10.3324/haematol.2013.087338

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, et al.

Bone Marrow Transplantation (2014) 49, 280–286; doi:10.1038/bmt.2013.170; Epub 2013 Nov 11

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.
Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, et al.

Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, et al.

Blood. 2010 Dec 2;116(23):5045-9. doi: 10.1182/blood-2010-04-281873. Epub 2010 Sep 8.

Successful treatment of EBV-associated post-transplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.
Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, Prockop SE, Koehne G and O’Reilly RJ.

Clinical data on EBV targeted T-cell therapy for MS

P1657: Presented September 13, 2019 at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Preliminary safety and efficacy of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus-targeted T-cell immunotherapy for patients with progressive forms of multiple sclerosis. View Citation > View Poster >
M. Pender, S. Hodgkinson, S. Broadley, J. Lindsey, Z. Ioannides, D. Munson, K. Rasor, F. Forozan, P. Foubert, B. Aftab, L. Gamelin, W. Ye, J. Willmer, A. Bar-Or

EPO2229: Presented June 30, 2019 at 5th Congress of the European Academy of Neurology (EAN)

Preliminary phase 1 safety of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus (EBV)-targeted T-cell immunotherapy for patients with progressive multiple sclerosis (MS). View Citation > View Poster >
M. Pender, S. Hodgkinson, S. Broadley, J. Lindsey, Z. Ioannides, B. Aftab, D. Munson, K. Rasor, F. Forozan, P. Foubert, L. Gamelin, A. Feng, J. Willmer

JCI Insight. 2018 Nov 15;3(22). pii: 124714. doi: 10.1172/jci.insight.124714.

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. View Citation >
Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, Beagley L, Rehan S, Crooks P, Hopkins TJ, Blum S, Green KA, Ioannides ZA, Swayne A, Aftab BT, Hooper KD, Burrows SR, Thompson KM, Coulthard A, Khanna R.

Presented on October 26, 2017 at MSParis 2017 Congress, the 7th Joint Meeting of the ECTRIMS and ACTRIMS

Safety and clinical improvement in a phase I trial of autologous Epstein–Barr virus-specific T cell therapy in patients with progressive multiple sclerosis View Citation >
Pender M, Khanna R, et al.

Abstract P4.408, Presented on April 26, 2017 at AAN in Boston, MA.

Symptomatic and objective clinical improvement in progressive multiple sclerosis patients treated with autologous Epstein–Barr virus-specific T cell therapy: Interim results of a phase I trial View Citation >
Pender M, Csurhes P, Smith C, Douglas N, Neller M, Beagley L, Rehan S, Hopkins T, Thompson K, Blum S, Green K, Ioannides Z, Coulthard A, Hooper K, Burrows S, Khanna R

Multiple Sclerosis (Houndmills, Basingstoke, England). 2014;20(11):1541-1544. doi:10.1177/1352458514521888

Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis View Citation >
Pender M, Csurhes P, Smith C, et al.

EBV and MS connection – Epidemiology

Annals of neurology. 2010;67(6):824-830. doi:10.1002/ana.21978.

Primary Infection with the Epstein-Barr Virus and Risk of Multiple Sclerosis. View Citation >
Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A.

Neurology Neuroimmunology & Neuroinflammation. 2017;4(2):e318. doi:10.1212/NXI.0000000000000318.

Epstein-Barr–negative MS: a true phenomenon? View Citation >
Dobson R, Kuhle J, Middeldorp J, Giovannoni G.

Neurology Neuroimmunology & Neuroinflammation. 2017;4(3):e308. doi:10.1212/NXI.0000000000000308.

Time correlation between mononucleosis and initial symptoms of MS. View Citation >
Endriz J, Ho PP, Steinman L.

PLoS ONE. 2010;5(9):e12496. doi:10.1371/journal.pone.0012496

An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis. View Citation >
Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV

EBV presence in Brain of MS patients

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 7;5(4):e466. doi: 10.1212/NXI.0000000000000466. eCollection 2018 Jul

Molecular signature of Epstein-Barr virus infection in MS brain lesions View Citation >
Moreno MA, Or-Geva N, Aftab BT, Khanna R, Croze E, Steinman L, Han MH

Neurology. 2012 Jan 3;78(1):15-23. doi: 10.1212/WNL.0b013e31823ed057.

Association of innate immune activation with latent Epstein-Barr Virus in active MS lesions. View Citation >
Tzartos et.al

The Journal of Experimental Medicine.. 2007;204(12):2899-2912. doi:10.1084/jem.20071030.

Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. View Citation >
Serafini B, Rosicarelli B, Franciotta D, et al.

MS disease course and EBV activity

Annals of neurology. 2010;67(2):159-169.doi:10.1002/ana.21886.

Elevated EBNA1 Immune Responses Predict Conversion to Multiple Sclerosis. View Citation >
Lünemann JD, Tintoré M, Messmer B, et al.

EBV potential connection to the Pathophysiology of MS

Clinical & Translational Immunology. 2017;6(1):e126-. doi:10.1038/cti.2016.87.

Defective T-cell control of Epstein–Barr virus infection in multiple sclerosis. View Citation >
Pender MP, Csurhes PA, Burrows JM, Burrows SR.

The Neuroscientist. 2011;17(4):351-367. doi:10.1177/1073858410381531.

The Essential Role of Epstein-Barr Virus in the Pathogenesis of Multiple Sclerosis. View Citation >
Pender MP.

Abstract 867: Presented December 9, 2019 at 61st American Society of Hematology (ASH) Annual Meeting

Mutation of the CD28 Costimulatory Domain Confers Enhanced CAR T Cell Function
Justin C Boucher, Gongbo Li, Hiroshi Kotani, Maria L Cabral, Dylan Morrissey, Sae Bom Lee, Kristen Spitler, Nolan Beatty, Bishwas Shrestha1, Bin Yu, Aslamuzzaman Kazi, Xuefeng Wang, Said M Sebti, Marco L Davila

Abstract 4438: Presented December 9, 2019 at 61st American Society of Hematology (ASH) Annual Meeting

MDSC Suppression of CAR T cell can be Reduced by Targeted Signaling Disruption
Estelle V Cervantes, Justin C Boucher, Sae Bom Lee, Kristen Spitler, Kayla Reid, Marco L Davila

Abstract 2511: Presented June 4, 2019 at ASCO 2019 Annual Meeting

Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent. View Citation >Prasad S. Adusumilli, Marjorie Glass Zauderer, Valerie W. Rusch, Roisin O’Cearbhaill, Amy Zhu, Daniel Ngai, Erin McGee, Navin Chintala, John Messinger, Waseem Cheema, Elizabeth Halton, Claudia Diamonte, John Pineda, Alain Vincent, Shanu Modi, Stephen Barnett Solomon, David Randolph Jones, Renier J. Brentjens, Isabelle Riviere, Michel Sadelain

Abstract 2310. Presented on April 1, 2019 at American Association of Cancer Research (AACR) Annual Meeting 2019

Functional demonstration of CD19 chimeric antigen receptor (CAR) engineered Epstein-Barr virus (EBV) specific T cells: An off-the-shelf, allogeneic CAR T-cell immunotherapy platform View Citation >   View Presentation>
Rhine R. Shen, Christina D. Pham, Michelle Min Wu, Philippe Foubert, Tassja J. Spindler, Daniel J. Munson, Blake T. Aftab

Presentation CT036. Presented on March 31, 2019 at American Association of Cancer Research (AACR) Annual Meeting 2019

A Phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
View Citation >
Prasad S. Adusumilli, Marjorie Zauderer, Valerie Rusch, Roisin O’Cearbhaill, Amy Zhu, Daniel Ngai, Erin McGee, Navin Chintala, John Messinger, Alain Vincent, Elizabeth Halton, Claudia Diamonte, John Pineda, Shanu Modi, Steve Solomon, David R Jones, Renier Brentjens, Isabelle Riviere, Michel Sadelain

Nature Medicine. 2018 Dec 17 doi: 10.1038/s41591-018-0290-5

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.
View Citation >
Judith Feucht, Jie Sun, Justin Eyquem, Yu-Jui Ho, Zeguo Zhao, Josef Leibold, Anton Dobrin, Annalisa Cabriolu, Mohamad Hamieh & Michel Sadelain

Abstract 966. Presented on December 3, 2018 at 60th American Society of Hematology (ASH) Annual Meeting

Mutation of the CD28 Costimulatory Domain Confers Increased CAR T Cell Persistence and Decreased Exhaustion
View Citation > View Presentation >
Justin C Boucher, Gongbo Li, Bishwas Shrestha, Maria L Cabral, Dylan Morrissey, Lawrence Guan, Marco L Davila

JCI Insight. 2018 Sept 20

4-1BB enhancement of CAR T function requires NF-κB and TRAFs. View Citation >
Li G, Boucher J, Kotani H, Park K, Zhang Y, Shrestha B, Wang X, Guan L, Beatty N, Abate-Daga D, and Davila M.

J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092. Epub 2016 Jul 25.

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. View Citation >
Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS.

Oncoimmunology. 2016 Dec 23;6(2):e1273302. doi: 10.1080/2162402X.2016.1273302. eCollection 2017.

CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. View Citation >
Chen N, Morello A, Tano Z, Adusumilli PS.

Science. 2014 Dec 19;346(6216):1536-40. doi: 10.1126/science.aaa1292.

Detection of self-reactive CD8⁺ T cells with an anergic phenotype in healthy individuals. View Citation >
Maeda Y, Nishikawa H, Sugiyama D, Ha D, Hamaguchi M, Saito T, Nishioka M, Wing JB, Adeegbe D, Katayama I, Sakaguchi S.

Nat Biotechnol. 2013 Jan;31(1):33-4. doi: 10.1038/nbt.2471.

Double or nothing on cancer immunotherapy. View Citation >
Hanada K, Restifo NP.

Abstract 747. Presented on December 11, 2017 at 59th American Society of Hematology Annual Meeting and Exposition (ASH), Atlanta, GA

Adoptive T-Cell Therapy With 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant
View Citation >
Susan Prockop, Ekaterina Doubrovina, Irene Rodriguez-Sanchez, Aisha N. Hasan, Juliet Barker, H.R. Castro-Malaspina, Parastoo B. Dahi, Sergio A. Giralt, Boglarka Gyurkocza, Nancy A. Kernan, Guenther Koehne, Esperanza B. Papadopoulos, Doris Ponce, Craig S. Sauter, Virginia Escobedo, Victoria Szenes, Karim Baroudy, Alison Slocum, Richard J. O’Reilly

Abstract 3157 presented December 6, 2015 at the American Society of Hematology Annual Meeting 2015.

Successful Treatment of Refractory CMV Chorioretinitis and Meningoencephalitis with Adoptive Transfer of Third Party CMVpp65 Specific T-Cell Lines. View Citation >
Prockop SE, Hasan AN, Doubrovina E, Castro-Malaspina HR, Barker JN, Dahi PB, Boulad F, Kernan NA, Koehne G, Sauter CS, Kiss S, Patel M, Suser S, O’Reilly RJ.

Biol Blood Marrow Transplant. 2015 May 29. pii: S1083-8791(15)00372-9. doi: 10.1016/j.bbmt.2015.05.015. [Epub ahead of print]

Immunotherapy with Donor T- Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent CMV Infection or Viremia. View Citation >
Koehne G, Hasan A, Doubrovina E, Prockop S, Tyler E, Wasilewski G, O’Reilly RJ.

Ophthalmic Surg Lasers Imaging Retina. 2015 Jan;46(1):80-2. doi: 10.3928/23258160-20150101-14.

Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion. View Citation >
Gupta MP, Coombs P, Prockop SE, Hasan AA, Doubrovina E, O’Reilly RJ, Cohen SH, Park SS, Kiss S.

Blood (ASH Annual Meeting Abstracts) 2014: Abstract 309. Presented on December 8th, 2014 at the American Society of Hematology Annual Meeting 2014.

Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients. View Citation >
Hasan AN, Prockop SE, Koehne G, Doubrovina E, and O’Reilly RJ.

Blood (ASH Annual Meeting Abstracts) 2014: Abstract 184. Presented on December 7th, 2014 at the American Society of Hematology Annual Meeting 2014.

Third Party Donor Derived CMV Specific T Cells for the Treatment of Refractory CMV Viremia and Disease after Hematopoietic Stem Cell Transplant. View Citation >
Prockop SE, Hasan AN, Koehne G, Doubrovina E, Sauter CS, Barker JN, Baroudy K, Boulad F, Giralt G, Khalaf R, Kernan NA, Papadopoulos EB, Ponce DM, Scaradavou A, Suser S, Wasilewski G, and O’Reilly RJ.

Abstract presented March 28, 2017 at EBMT in Marseille, France

Wilms’ Tumor 1 Protein is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches in Patients With Relapsed/Refractory Myeloma and Plasma Cell Leukemia View Citation >
Koehne G, Devlin S, Doubrovina E, Landau H, Hassouon H, Lesokhin A, Lendvai N, Chung D, Landgren O, Giralt S, O’Reilly RJ.

Abstract 98 presented December 5, 2015 at the American Society of Hematology Annual Meeting 2015.

Wilms’ Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches. View Citation >
Koehne G, Kosuri S, Doubrovina E, Dao T, Scott A, Jungbluth A, O’Reilly RJ.

Blood. 2013 Jan 10; 121(2):308-17. doi: 10.1182/blood-2012-06-435040. Epub 2012 Nov 16

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. View Citation >
Tyler EM, Jungbluth AA, O’Reilly RJ, Koehne G.

Blood. 2012 Aug 23;120(8):1633-46. doi: 10.1182/blood-2011-11-394619. Epub 2012 May 23

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. View Citation >
Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O’Reilly RJ.

Abstract presented March 28, 2017 at EBMT in Marseille, France

Wilms’ Tumor 1 Protein is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches in Patients With Relapsed/Refractory Myeloma and Plasma Cell Leukemia View Citation >
Koehne G, Devlin S, Doubrovina E, Landau H, Hassouon H, Lesokhin A, Lendvai N, Chung D, Landgren O, Giralt S, O’Reilly RJ.